Vaccine maker Moderna says the Food and Drug Administration will decide whether to approve its new flu shot for older adults ...

With the reversal from the FDA, Moderna said it is aiming to make the vaccine available for the 2026-27 flu season.

Moderna announced that the FDA will review its new mRNA flu vaccine, a reversal less than two weeks after the agency refused ...

The FDA is slated to make a decision on the flu shot on Aug. 5, which will allow Moderna to make the vaccine available for ...

Moderna announced that the FDA agreed to review its application for a mRNA-based flu vaccine after it agreed to further study ...

Moderna held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu vaccine that uses mRNA technology.

The Food and Drug Administration has reversed its shocking refusal to consider Moderna’s mRNA flu vaccine for approval.

The study involved 550 healthy U.S. adults ages 18 to 75 who received either the experimental combo vaccine and a placebo or ...

The Food and Drug Administration's about-face comes a little more than a week after the agency refused to consider the company's application to market the new kind of influenza vaccine.

The Food and Drug Administration (FDA) has backtracked its initial decision last week of refusing to review Moderna’s mRNA ...

By Mariam Sunny and Michael Erman Feb 18 (Reuters) - Moderna said on Wednesday the U.S. Food and Drug Administration changed course and will review its new flu vaccine, a week after rejecting the ...

After initially rejecting Moderna’s application for review, the FDA will now consider the company’s mRNA flu shot ...